Get Involved
On the day

Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Posted:

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.

Read the full article here.

Previous post
Back to list
Next post